Company profile: Titan Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of proprietary therapeutics and subdermal implant drug delivery solutions targeting serious medical disorders. Offerings include ProNeura, a continuous, long-term subdermal delivery platform for chronic conditions; Probuphine, a buprenorphine implant for maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less of oral buprenorphine daily; and a nalmefene implant to prevent relapse after detoxification.
Products and services
- Probuphine: First slow-release buprenorphine hydrochloride implant designed to maintain stable round-the-clock blood levels for maintenance treatment of opioid use disorder in clinically stable patients on ≤8 mg of oral buprenorphine daily
- ProNeura: Subdermal drug delivery platform providing continuous, long-term release of medication through an implant for treating chronic conditions
- Nalmefene Implant: Implant-based product engineered to prevent relapse in patients with opioid use disorder after detoxification
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Titan Pharmaceuticals
Diagnamed
HQ: Canada
Website
- Description: Provider of digital health AI platforms and tools to improve brain health, including BRAIN AGE AI for estimating brain age and assessing cognitive decline using EEG and machine learning; CERVAI Brain Health AI for assessments and research with generative AI; Dr. GenAI, a healthcare chatbot; PalGPT.ai for brain health applications; and FormGPT.io for healthcare applications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Diagnamed company profile →
Iama Therapeutics
HQ: Italy
Website
- Description: Provider of novel neuroscience therapeutics for pediatric brain disorders, advancing drug discovery to address unmet needs; lead candidate IAMA-6 is an orally administered small molecule targeting NKCC1-associated neuronal hyperexcitability, currently in Phase 1 clinical trials for autism and epilepsy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Iama Therapeutics company profile →
Cognito Therapeutics
HQ: United States
Website
- Description: Provider of non-invasive gamma wave therapy that evokes brain gamma activity via visual and auditory stimulation to slow cognitive and functional decline in Alzheimer’s; personalized intensity guided by EEG. Runs the HOPE pivotal study and Phase 2 OVERTURE showing preserved cognition, daily function, and brain volume. Holds FDA Breakthrough Device Designation; developing disease-modifying treatments for CNS illnesses.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cognito Therapeutics company profile →
Allon Therapeutics
HQ: Canada
Website
- Description: Provider of clinical-stage biopharmaceutical drug development for neurodegenerative diseases, with lead product Davunetide intranasal in Phase IIa clinical trials for Alzheimer's disease, schizophrenia cognitive impairment, and frontotemporal.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Allon Therapeutics company profile →
Alzheon
HQ: United States
Website
- Description: Provider of clinical-stage treatments for neurodegenerative disorders, including ALZ-801/valiltramiprosate, an oral treatment in Phase 3 testing for Alzheimer’s disease designed to inhibit amyloid oligomer formation; a discovery platform for small molecule inhibitors of protein misfolding; and an expanded access policy for investigational drugs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alzheon company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Titan Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Titan Pharmaceuticals
2.2 - Growth funds investing in similar companies to Titan Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Titan Pharmaceuticals
4.2 - Public trading comparable groups for Titan Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →